Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 201 articles:
HTML format



Single Articles


    August 2020
  1. AN X, Lei X, Huang R, Luo R, et al
    Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
    Cancer. 2020;126 Suppl 16:3837-3846.
    PubMed     Abstract available


  2. YANG H, Zhang S, Liu P, Cheng L, et al
    Use of high-resolution full-field optical coherence tomography and dynamic cell imaging for rapid intraoperative diagnosis during breast cancer surgery.
    Cancer. 2020;126 Suppl 16:3847-3856.
    PubMed     Abstract available


  3. GUO R, Su Y, Si J, Xue J, et al
    A nomogram for predicting axillary pathologic complete response in hormone receptor-positive breast cancer with cytologically proven axillary lymph node metastases.
    Cancer. 2020;126 Suppl 16:3819-3829.
    PubMed     Abstract available


  4. KHURI FR, O'Regan RM
    Progress in breast cancer research amid the COVID-19 gloom.
    Cancer. 2020;126 Suppl 16:3809-3810.
    PubMed    


  5. TANG Y, Zhang YJ, Zhang N, Shi M, et al
    Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes.
    Cancer. 2020;126 Suppl 16:3857-3866.
    PubMed     Abstract available


  6. PAN H, Zhang K, Wang M, Ling L, et al
    The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population-based observational study.
    Cancer. 2020;126 Suppl 16:3830-3836.
    PubMed     Abstract available


  7. XU B, Hu X, Feng J, Geng C, et al
    Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
    Cancer. 2020;126 Suppl 16:3867-3882.
    PubMed     Abstract available


  8. FAN Y, Xu B
    Current clinical trials on breast cancer in China: A systematic literature review.
    Cancer. 2020;126 Suppl 16:3811-3818.
    PubMed     Abstract available


  9. CHRISTGEN M, Gluz O, Harbeck N, Kates RE, et al
    Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
    Cancer. 2020 Aug 11. doi: 10.1002/cncr.33104.
    PubMed     Abstract available


  10. KIM EY, Chang Y, Ahn J, Yun JS, et al
    Mammographic breast density, its changes, and breast cancer risk in premenopausal and postmenopausal women.
    Cancer. 2020 Aug 7. doi: 10.1002/cncr.33138.
    PubMed     Abstract available


  11. PAN IW, Yen TWF, Huo J, Chen C, et al
    Choice of local therapy for young women with early-stage breast cancer who have young-aged children.
    Cancer. 2020 Aug 5. doi: 10.1002/cncr.33099.
    PubMed     Abstract available


    July 2020
  12. KUNTE S, Abraham J, Montero AJ
    Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
    Cancer. 2020 Jul 28. doi: 10.1002/cncr.33102.
    PubMed     Abstract available


  13. TROGDON JG, Liu X, Reeder-Hayes KE, Rotter J, et al
    Productivity costs associated with metastatic breast cancer in younger, midlife, and older women.
    Cancer. 2020 Jul 10. doi: 10.1002/cncr.33077.
    PubMed     Abstract available


  14. SHEPPARD VB, Dash C, Nomura S, Sutton AL, et al
    Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
    Cancer. 2020 Jul 2. doi: 10.1002/cncr.33054.
    PubMed     Abstract available


  15. PRINTZ C
    Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.
    Cancer. 2020;126:2955.
    PubMed    


    June 2020
  16. SUAREZ-ALMAZOR ME, Herrera R, Lei X, Chavez-MacGregor M, et al
    Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab.
    Cancer. 2020 Jun 23. doi: 10.1002/cncr.33035.
    PubMed     Abstract available


  17. PAN K, Chlebowski RT, Mortimer JE, Gunther MJ, et al
    Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women's Health Initiative.
    Cancer. 2020 Jun 12. doi: 10.1002/cncr.33002.
    PubMed     Abstract available


  18. IBRAHEEM A, Olopade OI, Huo D
    Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
    Cancer. 2020 Jun 10. doi: 10.1002/cncr.32956.
    PubMed     Abstract available


  19. DANCIU OC, Chen Z, Hoskins KF
    If you don't measure it, you can't improve it: Success and shortcomings of genomic assays in early breast cancer.
    Cancer. 2020 Jun 10. doi: 10.1002/cncr.32955.
    PubMed    


  20. MA S, Shepard DS, Ritter GA, Martell RE, et al
    The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32976.
    PubMed     Abstract available


    May 2020
  21. CACHO-DIAZ B, Salmeron-Moreno K, Alvarez-Alvarez A, Mendoza-Olivas LG, et al
    Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms.
    Cancer. 2020 May 26. doi: 10.1002/cncr.32928.
    PubMed     Abstract available


  22. SHARIFI MN, Anandan A, Grogan P, O'Regan RM, et al
    Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
    Cancer. 2020 May 19. doi: 10.1002/cncr.32931.
    PubMed     Abstract available


  23. ROSITCH AF, Unger-Saldana K, DeBoer RJ, Ng'ang'a A, et al
    The role of dissemination and implementation science in global breast cancer control programs: Frameworks, methods, and examples.
    Cancer. 2020;126 Suppl 10:2394-2404.
    PubMed     Abstract available


  24. MUTEBI M, Anderson BO, Duggan C, Adebamowo C, et al
    Breast cancer treatment: A phased approach to implementation.
    Cancer. 2020;126 Suppl 10:2365-2378.
    PubMed     Abstract available


  25. DVALADZE A, Kizub DA, Cabanes A, Nakigudde G, et al
    Breast cancer patient advocacy: A qualitative study of the challenges and opportunities for civil society organizations in low-income and middle-income countries.
    Cancer. 2020;126 Suppl 10:2439-2447.
    PubMed     Abstract available


  26. HORTON S, Camacho Rodriguez R, Anderson BO, Aung S, et al
    Health system strengthening: Integration of breast cancer care for improved outcomes.
    Cancer. 2020;126 Suppl 10:2353-2364.
    PubMed     Abstract available


  27. GINSBURG O, Yip CH, Brooks A, Cabanes A, et al
    Breast cancer early detection: A phased approach to implementation.
    Cancer. 2020;126 Suppl 10:2379-2393.
    PubMed     Abstract available


  28. HENDERSON V, Tossas-Milligan K, Martinez E, Williams B, et al
    Implementation of an integrated framework for a breast cancer screening and navigation program for women from underresourced communities.
    Cancer. 2020;126 Suppl 10:2481-2493.
    PubMed     Abstract available


  29. SCHEEL JR, Giglou MJ, Segel S, Orem J, et al
    Breast cancer early detection and diagnostic capacity in Uganda.
    Cancer. 2020;126 Suppl 10:2469-2480.
    PubMed     Abstract available


  30. DVALADZE A, Duggan C, Anderson BO
    Phased implementation for breast cancer management in low-income and middle-income countries: A proposal for the strategic application of resource-stratified guidelines by the Breast Health Global Initiative.
    Cancer. 2020;126 Suppl 10:2337-2338.
    PubMed    


  31. PRINTZ C
    Addition of tucatinib to trastuzumab and chemotherapy improves survival for patients with metastatic, HER2-positive breast cancer.
    Cancer. 2020;126:2113.
    PubMed    


  32. MA D, Jiang YZ, Xiao Y, Xie MD, et al
    Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Cancer. 2020 May 8. doi: 10.1002/cncr.32922.
    PubMed     Abstract available


  33. BROWN LC, Murphy AR, Lalonde CS, Subhedar PD, et al
    Posttraumatic stress disorder and breast cancer: Risk factors and the role of inflammation and endocrine function.
    Cancer. 2020 May 6. doi: 10.1002/cncr.32934.
    PubMed     Abstract available


    April 2020
  34. ZHOU J, Wang H, Fu F, Li Z, et al
    Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Cancer. 2020 Apr 27. doi: 10.1002/cncr.32905.
    PubMed     Abstract available


  35. NYROP KA, Deal AM, Reeve BB, Basch E, et al
    Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.
    Cancer. 2020 Apr 21. doi: 10.1002/cncr.32898.
    PubMed     Abstract available


  36. REIS JC, Travado L, Antoni MH, Oliveira FPM, et al
    Negative affect and stress-related brain metabolism in patients with metastatic breast cancer.
    Cancer. 2020 Apr 14. doi: 10.1002/cncr.32902.
    PubMed     Abstract available


  37. CONTE P, Schneeweiss A, Loibl S, Mamounas EP, et al
    Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Cancer. 2020 Apr 14. doi: 10.1002/cncr.32873.
    PubMed     Abstract available


  38. HILD S, Johanet M, Valenza A, Thabaud M, et al
    Quality of decision aids developed for women at average risk of breast cancer eligible for mammographic screening: Systematic review and assessment according to the international patient decision aid standards instrument.
    Cancer. 2020 Apr 8. doi: 10.1002/cncr.32858.
    PubMed     Abstract available


  39. FARVID MS, Spence ND, Holmes MD, Barnett JB, et al
    Fiber consumption and breast cancer incidence: A systematic review and meta-analysis of prospective studies.
    Cancer. 2020 Apr 6. doi: 10.1002/cncr.32816.
    PubMed     Abstract available


    March 2020
  40. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Prentice RL, et al
    Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women.
    Cancer. 2020 Mar 25. doi: 10.1002/cncr.32846.
    PubMed     Abstract available


  41. SHARIFF-MARCO S, Gomez SL, Canchola AJ, Fullington H, et al
    Nativity, ethnic enclave residence, and breast cancer survival among Latinas: Variations between California and Texas.
    Cancer. 2020 Mar 17. doi: 10.1002/cncr.32845.
    PubMed     Abstract available


  42. HERCULES SM, Hercules JC, Ansari A, Date SAJ, et al
    High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32771.
    PubMed     Abstract available


  43. MUKAMA T, Kharazmi E, Sundquist K, Sundquist J, et al
    Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32815.
    PubMed     Abstract available


  44. CHEN L, Alexanderson KAE
    Trajectories of sickness absence and disability pension in the 2 years before and 3 years after breast cancer diagnosis: A Swedish longitudinal population-based cohort study.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32820.
    PubMed     Abstract available


  45. PRINTZ C
    First person profile: Dennis J. Slamon, MD, PhD: Dr. Slamon's pioneering work helped lead to the breakthrough breast cancer drug trastuzumab, which has saved and extended the lives of millions of patients.
    Cancer. 2020;126:919-920.
    PubMed    


    February 2020
  46. AVIS NE, Levine B, Goyal N, Crawford SL, et al
    Health-related quality of life among breast cancer survivors and noncancer controls over 10 years: Pink SWAN.
    Cancer. 2020 Feb 27. doi: 10.1002/cncr.32757.
    PubMed     Abstract available


  47. PETERSON LL, Park S, Park Y, Colditz GA, et al
    Dietary advanced glycation end products and the risk of postmenopausal breast cancer in the National Institutes of Health-AARP Diet and Health Study.
    Cancer. 2020 Feb 25. doi: 10.1002/cncr.32798.
    PubMed     Abstract available


  48. PRINTZ C
    Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    Cancer. 2020;126:693.
    PubMed    


  49. XU Z, Tian S, Kong LQ
    On the proportion of male breast cancer among all breast cancers.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32731.
    PubMed    


  50. YADAV S, Karam D, Bin Riaz I, Xie H, et al
    Reply to On the proportion of male breast cancer among all breast cancers.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32727.
    PubMed    


  51. VYSOTSKAIA V, Kaseniit KE, Bucheit L, Ready K, et al
    Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Cancer. 2020;126:549-558.
    PubMed     Abstract available


    January 2020
  52. JATOI I
    Residual confounding threatens the validity of observational studies on breast cancer local therapy.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32741.
    PubMed    


  53. KURIAN AW, Canchola AJ, Gomez SL
    Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32743.
    PubMed    


  54. WEIDNER AE, Liggin ME, Zuniga BI, Tezak AL, et al
    Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    Cancer. 2020 Jan 22. doi: 10.1002/cncr.32715.
    PubMed     Abstract available


  55. SONG Y, Barry WT, Seah DS, Tung NM, et al
    Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Cancer. 2020;126:271-280.
    PubMed     Abstract available


  56. GUO F, Scholl M, Fuchs EL, Berenson AB, et al
    BRCA testing in unaffected young women in the United States, 2006-2017.
    Cancer. 2020;126:337-343.
    PubMed     Abstract available


  57. HERSHMAN DL, Accordino MK, Shen S, Buono D, et al
    Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events.
    Cancer. 2020 Jan 8. doi: 10.1002/cncr.32690.
    PubMed     Abstract available


  58. SHIN DW, Yu J, Cho J, Lee SK, et al
    Breast cancer screening disparities between women with and without disabilities: A national database study in South Korea.
    Cancer. 2020 Jan 6. doi: 10.1002/cncr.32693.
    PubMed     Abstract available


  59. PRINTZ C
    Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy.
    Cancer. 2020;126:1827.
    PubMed    


  60. PRINTZ C
    Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement.
    Cancer. 2020;126:1827.
    PubMed    


    December 2019
  61. DOWNS-CANNER SM, Gaber CE, Louie RJ, Strassle PD, et al
    Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.
    Cancer. 2019 Dec 20. doi: 10.1002/cncr.32668.
    PubMed     Abstract available


  62. MANDELBLATT JS, Zhai W, Ahn J, Small BJ, et al
    Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study.
    Cancer. 2019 Dec 20. doi: 10.1002/cncr.32663.
    PubMed     Abstract available


  63. PAPAKONSTANTINOU A, Matikas A, Bengtsson NO, Malmstrom P, et al
    Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial.
    Cancer. 2019 Dec 18. doi: 10.1002/cncr.32653.
    PubMed     Abstract available


  64. ROBERTS AW, Fergestrom N, Neuner JM, Winn AN, et al
    New-onset persistent opioid use following breast cancer treatment in older adult women.
    Cancer. 2019 Dec 17. doi: 10.1002/cncr.32593.
    PubMed     Abstract available


  65. AFIFI AM, Saad AM, Al-Husseini MJ, Elmehrath AO, et al
    Causes of death after breast cancer diagnosis: A US population-based analysis.
    Cancer. 2019 Dec 16. doi: 10.1002/cncr.32648.
    PubMed     Abstract available


  66. HUMPHRIES B, Lauzier S, Drolet M, Coyle D, et al
    Wage losses among spouses of women with nonmetastatic breast cancer.
    Cancer. 2019 Dec 10. doi: 10.1002/cncr.32638.
    PubMed     Abstract available


  67. PRINTZ C
    First person profile: Joseph Sparano, MD: A respected physician and researcher, Dr. Sparano led the practice-changing TAILORx clinical trial for breast cancer treatment and is working to close disparities in cancer care.
    Cancer. 2019;125:4121-4123.
    PubMed    


    November 2019
  68. LE D, Speers C, Thompson L, Gondara L, et al
    The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Cancer. 2019 Nov 21. doi: 10.1002/cncr.32631.
    PubMed     Abstract available


  69. KURIAN AW, Canchola AJ, Ma CS, Clarke CA, et al
    Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015.
    Cancer. 2019 Nov 21. doi: 10.1002/cncr.32618.
    PubMed     Abstract available


  70. HO AY, Barker CA, Arnold BB, Powell SN, et al
    A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
    Cancer. 2019 Nov 20. doi: 10.1002/cncr.32599.
    PubMed     Abstract available


  71. BOWEN DJ, Shinn EH, Gregrowski S, Kimmick G, et al
    Patient-reported outcomes in the Translational Breast Cancer Research Consortium.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32615.
    PubMed     Abstract available


  72. IM EO, Kim S, Yang YL, Chee W, et al
    The efficacy of a technology-based information and coaching/support program on pain and symptoms in Asian American survivors of breast cancer.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32579.
    PubMed     Abstract available


    October 2019
  73. MALMGREN JA, Calip GS, Atwood MK, Mayer M, et al
    Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32531.
    PubMed     Abstract available


  74. LETOURNEAU JM, Wald K, Sinha N, Juarez-Hernandez F, et al
    Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32546.
    PubMed     Abstract available


  75. YADAV S, Karam D, Bin Riaz I, Xie H, et al
    Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century.
    Cancer. 2019 Oct 7. doi: 10.1002/cncr.32472.
    PubMed     Abstract available


    September 2019
  76. HALEY JS, Hibler EA, Zhou S, Schmitz KH, et al
    Dose-dependent effect of aerobic exercise on inflammatory biomarkers in a randomized controlled trial of women at high risk of breast cancer.
    Cancer. 2019 Sep 30. doi: 10.1002/cncr.32530.
    PubMed     Abstract available


  77. CARROLL JE, Small BJ, Tometich DB, Zhai W, et al
    Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype.
    Cancer. 2019 Sep 25. doi: 10.1002/cncr.32489.
    PubMed     Abstract available


  78. JOHNS SA, Stutz PV, Talib TL, Cohee AA, et al
    Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.
    Cancer. 2019 Sep 20. doi: 10.1002/cncr.32518.
    PubMed     Abstract available


  79. PRINTZ C
    First person profile: Leslie Bernstein, PhD: An epidemiologist known for her groundbreaking discoveries about breast cancer, Dr. Bernstein continues to push the field forward.
    Cancer. 2019;125:2907-2909.
    PubMed    


    August 2019
  80. LEE J, Hur H, Lee JW, Youn HJ, et al
    Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32485.
    PubMed     Abstract available


  81. EWER SM, Pham DD
    Late-onset heart failure after treatment for breast cancer.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32483.
    PubMed    


  82. FREUND KM, Haas JS, Lemon SC, Burns White K, et al
    Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study.
    Cancer. 2019 Aug 26. doi: 10.1002/cncr.32432.
    PubMed     Abstract available


  83. METCALFE KA, Retrouvey H, Kerrebijn I, Butler K, et al
    Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer.
    Cancer. 2019 Aug 22. doi: 10.1002/cncr.32405.
    PubMed     Abstract available


  84. WANG T, McCullough LE, White AJ, Bradshaw PT, et al
    Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
    Cancer. 2019 Aug 12. doi: 10.1002/cncr.32364.
    PubMed     Abstract available


  85. MALECKI KMC
    Epigenetics and differential effects of aspirin on breast cancer survival: Opportunities for understanding human susceptibility and risk.
    Cancer. 2019 Aug 12. doi: 10.1002/cncr.32365.
    PubMed    


  86. REEDER-HAYES KE, Mayer SE, Olshan AF, Wheeler SB, et al
    Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32378.
    PubMed     Abstract available


  87. MILES RC, Lehman CD, Mercaldo SF, Tamimi RM, et al
    Obesity and breast cancer screening: Cross-sectional survey results from the behavioral risk factor surveillance system.
    Cancer. 2019 Aug 8. doi: 10.1002/cncr.32430.
    PubMed     Abstract available


  88. NEUNER JM, Fergestrom NM, Laud PW, Nattinger AB, et al
    The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.
    Cancer. 2019 Aug 2. doi: 10.1002/cncr.32433.
    PubMed     Abstract available


  89. MANZ CR
    Getting in sync with adherence to endocrine therapy in breast cancer.
    Cancer. 2019 Aug 2. doi: 10.1002/cncr.32434.
    PubMed    


  90. PRINTZ C
    First person profile: Larry Norton, MD: A world-renowned breast cancer researcher, Dr. Norton has used his passion for music and math to revolutionize oncology.
    Cancer. 2019;125:2525-2527.
    PubMed    


    July 2019
  91. PEREZ EA, Barrios C, Eiermann W, Toi M, et al
    Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Cancer. 2019 Jul 18. doi: 10.1002/cncr.32392.
    PubMed     Abstract available


  92. DUSTIN D, Gu G, Fuqua SAW
    ESR1 mutations in breast cancer.
    Cancer. 2019 Jul 18. doi: 10.1002/cncr.32345.
    PubMed     Abstract available


  93. PRINTZ C
    Study: Patients with HER2-positive, stage IV breast cancer experienced better survival with surgery.
    Cancer. 2019;125:2337.
    PubMed    


  94. SCOTT LC, Mobley LR, Kuo TM, Il'yasova D, et al
    Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014.
    Cancer. 2019 Jul 8. doi: 10.1002/cncr.32207.
    PubMed     Abstract available


    June 2019
  95. MORI M, Fujimori M, van Vliet LM, Yamaguchi T, et al
    Explicit prognostic disclosure to Asian women with breast cancer: A randomized, scripted video-vignette study (J-SUPPORT1601).
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32327.
    PubMed     Abstract available


  96. LILLEBORGE M, Falk RS, Russnes H, Sauer T, et al
    Risk of breast cancer by prior screening results among women participating in BreastScreen Norway.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32330.
    PubMed     Abstract available


  97. WEITZEL JN, Neuhausen SL, Adamson A, Tao S, et al
    Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32083.
    PubMed     Abstract available


  98. WALSH SM, Zabor EC, Stempel M, Morrow M, et al
    Does race predict survival for women with invasive breast cancer?
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32296.
    PubMed     Abstract available


  99. NAROD SA
    Genetic testing for breast cancer in the Hispanic community.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32334.
    PubMed    


  100. MEISEL JL, O'Regan RM
    Race, breast cancer, and prognosis: Where biology is queen?
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32294.
    PubMed    


  101. SUNG H, DeSantis CE, Fedewa SA, Kantelhardt EJ, et al
    Breast cancer subtypes among Eastern-African-born black women and other black women in the United States.
    Cancer. 2019 Jun 13. doi: 10.1002/cncr.32293.
    PubMed     Abstract available


    May 2019
  102. FAYANJU OM, Yenokyan K, Ren Y, Goldstein BA, et al
    The effect of treatment on patient-reported distress after breast cancer diagnosis.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32174.
    PubMed     Abstract available


  103. WASSERMANN J, Gelber SI, Rosenberg SM, Ruddy KJ, et al
    Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32192.
    PubMed     Abstract available


  104. HENRY NL, Cannon-Albright LA
    Breast cancer histologic subtypes show excess familial clustering.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32198.
    PubMed     Abstract available


  105. LIU Y, West R, Weber JD, Colditz GA, et al
    Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32200.
    PubMed     Abstract available


  106. NYROP KA, Deal AM, Reeder-Hayes KE, Shachar SS, et al
    Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Cancer. 2019 May 15. doi: 10.1002/cncr.32175.
    PubMed     Abstract available


  107. DEMISSEI BG, Finkelman BS, Hubbard RA, Zhang L, et al
    Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy.
    Cancer. 2019 May 1. doi: 10.1002/cncr.32149.
    PubMed     Abstract available


    April 2019
  108. LYNCH BM, Nguyen NH, Moore MM, Reeves MM, et al
    A randomized controlled trial of a wearable technology-based intervention for increasing moderate to vigorous physical activity and reducing sedentary behavior in breast cancer survivors: The ACTIVATE Trial.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32143.
    PubMed     Abstract available


  109. HAWKINS BRESSLER L, Mersereau JE, Anderson C, Rodriguez JL, et al
    Fertility-related experiences after breast cancer diagnosis in the Sister and Two Sister Studies.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32126.
    PubMed     Abstract available


  110. PRINTZ C
    Substituting adjuvant trastuzumab emtansine for Herceptin improves survival in patients with human epidermal growth factor receptor 2-positive breast cancer.
    Cancer. 2019;125:1213.
    PubMed    



  111. "Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y.
    Cancer. 2019;125:1200.
    PubMed     Abstract available


  112. PRINTZ C
    Circulating tumor cell count could be used to determine treatment of metastatic breast cancer.
    Cancer. 2019;125:1021.
    PubMed    


  113. RANA HQ, Sacca R, Drogan C, Gutierrez S, et al
    Prevalence of germline variants in inflammatory breast cancer.
    Cancer. 2019 Apr 1. doi: 10.1002/cncr.32062.
    PubMed     Abstract available


    March 2019
  114. YU KD, Wu SY, Liu GY, Wu J, et al
    Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
    Cancer. 2019 Mar 20. doi: 10.1002/cncr.32057.
    PubMed     Abstract available


  115. PRINTZ C
    Study projects a 43% increase in lung cancer mortality among women: New research suggests that, among women, strides in reducing global deaths from breast cancer could be tempered by rising lung cancer deaths. However, according to experts, the projec
    Cancer. 2019;125:831-832.
    PubMed    


  116. BAGLIA ML, Lin IH, Cartmel B, Sanft T, et al
    Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32051.
    PubMed     Abstract available


  117. DEAN LT, Moss SL, Rollinson SI, Frasso Jaramillo L, et al
    Patient recommendations for reducing long-lasting economic burden after breast cancer.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32012.
    PubMed     Abstract available


    February 2019
  118. AUMEERUDDY MZ, Mahomoodally MF
    Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32022.
    PubMed     Abstract available


  119. BALAZY KE, Benitez CM, Gutkin PM, Jacobson CE, et al
    Association between primary language, a lack of mammographic screening, and later stage breast cancer presentation.
    Cancer. 2019 Feb 15. doi: 10.1002/cncr.32027.
    PubMed     Abstract available


  120. GIANNAKEAS V, Narod SA
    The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.32008.
    PubMed    


  121. DUFFY SW, Smith RA, Tabar L, Dean PB, et al
    Reply to The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.32007.
    PubMed    


  122. HENDRICK RE, Baker JA, Helvie MA
    Breast cancer deaths averted over 3 decades.
    Cancer. 2019 Feb 11. doi: 10.1002/cncr.31954.
    PubMed     Abstract available


  123. PRINTZ C
    Black women less likely to adhere to hormone therapy for breast cancer.
    Cancer. 2019;125:331.
    PubMed    


  124. EUHUS DM, Addae JK, Snyder CF, Canner JK, et al
    Change in health-related quality of life in older women after diagnosis of a small breast cancer.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31993.
    PubMed     Abstract available


  125. WALLNER LP, Li Y, McLeod MC, Gargaro J, et al
    Primary care provider-reported involvement in breast cancer treatment decisions.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31998.
    PubMed     Abstract available


  126. PARTRIDGE AH, Ruddy KJ, Barry WT, Greaney ML, et al
    A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31984.
    PubMed     Abstract available


  127. WINN AN, Dusetzina SB
    More evidence on the limited impact of state oral oncology parity laws.
    Cancer. 2019;125:335-336.
    PubMed    


    January 2019
  128. BEDROSIAN I, Parker PA, Brewster AM
    Who should get a contralateral prophylactic mastectomy for breast cancer?
    Cancer. 2019 Jan 15. doi: 10.1002/cncr.31915.
    PubMed    


  129. IBRAHEEM AF, Press DJ, Olopade OI, Huo D, et al
    Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
    Cancer. 2019;125:213-222.
    PubMed     Abstract available


  130. AMMITZBOLL G, Johansen C, Lanng C, Andersen EW, et al
    Progressive resistance training to prevent arm lymphedema in the first year after breast cancer surgery: Results of a randomized controlled trial.
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31962.
    PubMed     Abstract available


  131. TAUB CJ, Lippman ME, Hudson BI, Blomberg BB, et al
    The effects of a randomized trial of brief forms of stress management on RAGE-associated S100A8/A9 in patients with breast cancer undergoing primary treatment.
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31965.
    PubMed     Abstract available


  132. VEENSTRA CM, Wallner LP, Abrahamse PH, Janz NK, et al
    Understanding the engagement of key decision support persons in patient decision making around breast cancer treatment.
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31956.
    PubMed     Abstract available


    December 2018
  133. CHIN AL, Bentley JP, Pollom EL
    The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Cancer. 2018 Dec 19. doi: 10.1002/cncr.31910.
    PubMed     Abstract available


  134. BOWER JE, Asher A, Garet D, Petersen L, et al
    Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31827.
    PubMed     Abstract available


  135. KOELMEYER LA, Borotkanics RJ, Alcorso J, Prah P, et al
    Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31873.
    PubMed     Abstract available


  136. SENEVIRATNE MG, Bozkurt S, Patel MI, Seto T, et al
    Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer.
    Cancer. 2018 Dec 4. doi: 10.1002/cncr.31895.
    PubMed     Abstract available


    November 2018
  137. DIELI-CONWRIGHT CM, Sweeney FC, Courneya KS, Tripathy D, et al
    Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise in survivors of breast cancer.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31879.
    PubMed     Abstract available


  138. BINES J, Tevaarwerk AJ
    Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2-targeted therapy.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31878.
    PubMed    


  139. VAN DYK K, Crespi CM, Bower JE, Castellon SA, et al
    The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment.
    Cancer. 2018 Nov 28. doi: 10.1002/cncr.31858.
    PubMed     Abstract available


  140. CARROLL JE, Van Dyk K, Bower JE, Scuric Z, et al
    Cognitive performance in survivors of breast cancer and markers of biological aging.
    Cancer. 2018 Nov 26. doi: 10.1002/cncr.31777.
    PubMed     Abstract available


  141. TABAR L, Dean PB, Chen TH, Yen AM, et al
    The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
    Cancer. 2018 Nov 8. doi: 10.1002/cncr.31840.
    PubMed     Abstract available


  142. KALINSKY K, O'Regan RM
    Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
    Cancer. 2018 Nov 2. doi: 10.1002/cncr.31814.
    PubMed    


  143. GREENWALD MK, Ruterbusch JJ, Beebe-Dimmer JL, Simon MS, et al
    Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Cancer. 2018 Nov 2. doi: 10.1002/cncr.31798.
    PubMed     Abstract available


  144. MAILHOT VEGA RB, Balogun OD, Ishaq OF, Bray F, et al
    Estimating child mortality associated with maternal mortality from breast and cervical cancer.
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31780.
    PubMed     Abstract available


    October 2018
  145. CAUDLE AS, Kuerer HM, Krishnamurthy S, Shin K, et al
    Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study.
    Cancer. 2018 Oct 25. doi: 10.1002/cncr.31825.
    PubMed     Abstract available


  146. LAMBERTINI M, Martel S, Campbell C, Guillaume S, et al
    Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
    Cancer. 2018 Oct 18. doi: 10.1002/cncr.31784.
    PubMed     Abstract available


  147. LANDEIRO LCG, Gagliato DM, Fede AB, Fraile NM, et al
    Return to work after breast cancer diagnosis: An observational prospective study in brazil.
    Cancer. 2018 Oct 17. doi: 10.1002/cncr.31735.
    PubMed     Abstract available


  148. HOSKINS KF, Tejeda S, Vijayasiri G, Chukwudozie IB, et al
    A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
    Cancer. 2018 Oct 15. doi: 10.1002/cncr.31635.
    PubMed     Abstract available


  149. ROCQUE GB, Williams CP, Kenzik KM, Jackson BE, et al
    Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
    Cancer. 2018 Oct 14. doi: 10.1002/cncr.31694.
    PubMed     Abstract available


  150. ROMANOFF A, Zabor EC, Petruolo O, Stempel M, et al
    Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?
    Cancer. 2018 Oct 11. doi: 10.1002/cncr.31757.
    PubMed     Abstract available


  151. CHLEBOWSKI RT, Luo J, Anderson GL, Barrington W, et al
    Weight loss and breast cancer incidence in postmenopausal women.
    Cancer. 2018 Oct 8. doi: 10.1002/cncr.31687.
    PubMed     Abstract available


  152. ANDERSON C, Nichols HB, Deal AM, Mark Park YM, et al
    Changes in cardiovascular disease risk and risk factors among women with and without breast cancer.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31775.
    PubMed     Abstract available


  153. PERNAS S, Barroso-Sousa R, Tolaney SM
    Optimal treatment of early stage HER2-positive breast cancer.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31657.
    PubMed     Abstract available


  154. GORNICK MC, Kurian AW, An LC, Fagerlin A, et al
    Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial.
    Cancer. 2018 Oct 5. doi: 10.1002/cncr.31731.
    PubMed     Abstract available


    September 2018
  155. KEHL KL, Niu J, Chavez-MacGregor M, Giordano SH, et al
    Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
    Cancer. 2018 Sep 28. doi: 10.1002/cncr.31760.
    PubMed     Abstract available


  156. KIM SJ, Glassgow AE, Watson KS, Molina Y, et al
    Gendered and Racialized Social Expectations, Barriers, and Delayed Breast Cancer Diagnosis.
    Cancer. 2018 Sep 24. doi: 10.1002/cncr.31636.
    PubMed     Abstract available


  157. GUO F, Kuo YF, Shih YCT, Giordano SH, et al
    Trends in Breast Cancer Mortality by Stage at Diagnosis Among Young Women in the United States.
    Cancer. 2018 Sep 6. doi: 10.1002/cncr.31638.
    PubMed     Abstract available



  158. MINDACT study results show low risk of local recurrence after 5 years for patients with early breast cancer.
    Cancer. 2018;124:3466-3467.
    PubMed    



  159. First person: George Sledge, Jr, MD: Former ASCO president leads breast cancer research and mentors Stanford faculty.
    Cancer. 2018;124:3465.
    PubMed    


    August 2018

  160. Many Women With the Most Common Form of Breast Cancer Can Skip Chemotherapy: Study finds that approximately 70% of patients with this form of the disease do not need adjuvant chemotherapy.
    Cancer. 2018;124:3281-2382.
    PubMed    


    July 2018
  161. JAGSI R, Ward KC, Abrahamse PH, Wallner LP, et al
    Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer.
    Cancer. 2018 Jul 23. doi: 10.1002/cncr.31532.
    PubMed     Abstract available


  162. DASH C, Taylor TR, Makambi KH, Hicks J, et al
    Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE study.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31569.
    PubMed     Abstract available


  163. PRINTZ C
    Older women with a family history of breast cancer face increased risk of the disease.
    Cancer. 2018;124:2673.
    PubMed    


    June 2018
  164. BAIL JR, Fruge AD, Cases MG, De Los Santos JF, et al
    A home-based mentored vegetable gardening intervention demonstrates feasibility and improvements in physical activity and performance among breast cancer survivors.
    Cancer. 2018 Jun 22. doi: 10.1002/cncr.31559.
    PubMed     Abstract available


  165. FRANK RD, Winham SJ, Vierkant RA, Frost MH, et al
    Evaluation of 2 breast cancer risk models in a benign breast disease cohort.
    Cancer. 2018 Jun 22. doi: 10.1002/cncr.31528.
    PubMed     Abstract available


    May 2018
  166. VALACHIS A, Mamounas EP, Mittendorf EA, Hayashi N, et al
    Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31518.
    PubMed     Abstract available


    April 2018
  167. SHUMWAY DA, Griffith KA, Hawley ST, Wallner LP, et al
    Patient views and correlates of radiotherapy omission in a population-based sample of older women with favorable-prognosis breast cancer.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31378.
    PubMed     Abstract available


  168. HIRTH JM, Hatch SS, Lin YL, Giordano SH, et al
    Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31393.
    PubMed     Abstract available


  169. TURK AA, Wisinski KB
    PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31307.
    PubMed     Abstract available


  170. SCOTT JM, Iyengar NM, Nilsen TS, Michalski M, et al
    Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31368.
    PubMed     Abstract available


  171. OLAGUNJU TO, Liu Y, Liang LJ, Stomber JM, et al
    Disparities in the survivorship experience among Latina survivors of breast cancer.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31342.
    PubMed     Abstract available


    March 2018
  172. UEMURA MI, French JT, Hess KR, Liu D, et al
    Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31336.
    PubMed     Abstract available


  173. SCHWARTZ KL, Simon MS, Bylsma LC, Ruterbusch JJ, et al
    Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Cancer. 2018 Mar 5. doi: 10.1002/cncr.31299.
    PubMed     Abstract available


  174. FREEDMAN RA, Keating NL, Lin NU, Winer EP, et al
    Breast cancer-specific survival by age: Worse outcomes for the oldest patients.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31308.
    PubMed     Abstract available


    February 2018
  175. PRINTZ C
    Patients with breast cancer who are treated with chemotherapy risk long-term nerve damage.
    Cancer. 2018;124:663.
    PubMed    


  176. EKENGA CC, Perez M, Margenthaler JA, Jeffe DB, et al
    Early-stage breast cancer and employment participation after 2 years of follow-up: A comparison with age-matched controls.
    Cancer. 2018 Feb 13. doi: 10.1002/cncr.31270.
    PubMed     Abstract available


  177. KWA MJ, Adams S
    Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Cancer. 2018 Feb 9. doi: 10.1002/cncr.31272.
    PubMed     Abstract available


    January 2018
  178. LITVAK A, Batukbhai B, Russell SD, Tsai HL, et al
    Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Cancer. 2018 Jan 30. doi: 10.1002/cncr.31260.
    PubMed     Abstract available


  179. REEDER-HAYES KE, Wheeler SB, Baggett CD, Zhou X, et al
    Influence of provider factors and race on uptake of breast cancer gene expression profiling.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31222.
    PubMed     Abstract available


  180. PILEWSKIE M, Morrow M
    Margins in breast cancer: How much is enough?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31221.
    PubMed     Abstract available


  181. SIMON MS, Beebe-Dimmer JL, Hastert TA, Manson JE, et al
    Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31230.
    PubMed     Abstract available


    December 2017
  182. BALTZELL KA, Shen HM, Krishnamurty S, Sison JD, et al
    Bovine leukemia virus linked to breast cancer but not coinfection with human papillomavirus: Case-control study of women in Texas.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31169.
    PubMed     Abstract available


  183. NUTTER EL, Weiss JE, Marotti JD, Barth RJ Jr, et al
    Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31202.
    PubMed     Abstract available


  184. ARUN BK, Gutierrez Barrera AM, Ueno NT
    Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31188.
    PubMed    


  185. ALTUNDAG K
    Diagnosis of patients with inflammatory breast cancer is a problematic issue.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31189.
    PubMed    


  186. MILLER JW, Smith JL, Ryerson AB, Tucker TC, et al
    Disparities in breast cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5100-5118.
    PubMed     Abstract available


  187. ROSENSTOCK AS, Niu J, Giordano SH, Zhao H, et al
    Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Cancer. 2017 Dec 13. doi: 10.1002/cncr.31144.
    PubMed     Abstract available


  188. OHRI N, Haffty BG, Buchholz TA
    The role of postmastectomy radiotherapy in patients with stage II breast cancer.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31130.
    PubMed    


  189. PRINTZ C
    Physicians discuss ramifications of studies pointing to breast cancer overdiagnosis: New research under way attempts to better define who should be screened and treated.
    Cancer. 2017;123:4525-4527.
    PubMed    


    November 2017
  190. MANNEVILLE F, Rotonda C, Conroy T, Bonnetain F, et al
    The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer.
    Cancer. 2017 Nov 8. doi: 10.1002/cncr.31108.
    PubMed     Abstract available


  191. OHRI N, Sittig MP, Tsai CJ, Hwang ES, et al
    Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31080.
    PubMed     Abstract available


  192. SENNERSTAM RB
    Reply to Imaging modalities for the detection of distant metastases in breast cancer patients diagnosed in the 1970s and 1990s: Does it make any sense?
    Cancer. 2017 Nov 6. doi: 10.1002/cncy.21924.
    PubMed    


  193. ALTUNDAG K
    Imaging modalities for the detection of distant metastases in breast cancer patients diagnosed in the 1970s and 1990s: Does it make any sense?
    Cancer. 2017 Nov 6. doi: 10.1002/cncy.21925.
    PubMed    


    October 2017
  194. WALLACE AS, Keene KS, Williams CP, Jackson BE, et al
    Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancer.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.30989.
    PubMed     Abstract available


  195. GUTIERREZ BARRERA AM, Fouad TM, Song J, Webster R, et al
    BRCA mutations in women with inflammatory breast cancer.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31069.
    PubMed     Abstract available


  196. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Abstract available


  197. DONALDSON AR, McCarthy C, Goraya S, Pederson HJ, et al
    Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31061.
    PubMed     Abstract available


  198. JAGSI R, Abrahamse PH, Lee KL, Wallner LP, et al
    Treatment decisions and employment of breast cancer patients: Results of a population-based survey.
    Cancer. 2017 Oct 9. doi: 10.1002/cncr.30959.
    PubMed     Abstract available


  199. ARLEO EK, Hendrick RE, Helvie MA, Sickles EA, et al
    Comparison of recommendations for screening mammography using CISNET models.
    Cancer. 2017;123:3673-3680.
    PubMed     Abstract available


    September 2017
  200. CHAOUL A, Milbury K, Spelman A, Basen-Engquist K, et al
    Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.30938.
    PubMed     Abstract available


  201. HARTMAN SJ, Nelson SH, Myers E, Natarajan L, et al
    Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study.
    Cancer. 2017 Sep 19. doi: 10.1002/cncr.30987.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: